Abstracts tagged "IgG4 Related Disease and biomarkers"

Abstract Number: 1765 • 2018 ACR/ARHP Annual Meeting
Cerebrospinal Fluid Biomarker of Disease Activity: Significance in ANCA-Related Hypertrophic Pachymeningitis
Yasuhiro Shimojima¹, Dai Kishida² and Yoshiki Sekijima², ¹Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan, ²Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan
Background/Purpose: Hypertrophic pachymeningitis (HP), which becomes the cause of chronic headache, seizure, and cranial neuropathy, is an inflammatory disorder demonstrating focal and diffuse thickening of…
Abstract Number: 2903 • 2017 ACR/ARHP Annual Meeting
Serum CC-Chemokine Ligand 18 Level Is a Potential Biomarker of Disease Activity in IgG4-Related Disease
Mitsuhiro Akiyama¹, Hidekata Yasuoka², Keiko Yoshimoto² and Tsutomu Takeuchi², ¹Division of Rheumatology, Department of Internal Medicine,, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic disorder characterized by severe fibrosis in lesions. In previous reports, CC-chemokine ligand 18 (CCL18) level is a substantial…
Abstract Number: 939 • 2016 ACR/ARHP Annual Meeting
Circulating IgG4 Antibody Secreting Cells Are Better Biomarker of Disease Activity Compared to Serum IgG4 Levels in Patients with IgG4-Related Disease
Arezou Khosroshahi¹, Alessia Corrado¹, Takashi Muraki², Shuya Kyu³, Xiaoqian Wang⁴, Ignacio Sanz⁵ and F. Eun-Hyung Lee¹, ¹Medicine, Emory University School of Medicine, Atlanta, GA, ²Pathology, Emory University School of Medicine, Atlanta, GA, ³Medicine/Rheumatology, Emory University School of Medicine, Atlanta, GA, ⁴Division of Rheumatology and Lowance Center for Human Immunology, Emory University School of Medicine, Atlanta, GA, ⁵Rheumatology and Lowance Center for Human Immunology, Emory University School of Medicine and Lowance Center for Human Immunology, Atlanta, GA
Background/Purpose: IgG4-related disease (IgG4-RD) is a fibro-inflammatory condition with a consistent set of pathological features that affect multiple organ systems. Patients with IgG4-RD typically present…
Abstract Number: 1102 • 2015 ACR/ARHP Annual Meeting
CD19+CD24-CD38hi B-Cell Subset: A Potential Biomarker for IgG4-Related Disease
Wen Zhang^1,2, Wei Lin³, Yu Chen⁴, Yunjiao Yang⁴, Hua Chen⁴, QingJun Wu⁴, Yunyun Fei⁴, Chaojun Hu⁴, Yongzhe Li³, Xuan Zhang³, Yan Zhao⁴, Fengchun Zhang³, Xiaofeng Zeng⁴ and Peter E. Lipsky⁵, ¹Rheuamtology, Peking Union Medical College Hospital, Beijing, China, ²Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, ³Peking Union Medical College Hospital, Beijing, China, ⁴Rheumatology, Peking Union Medical College Hospital, Beijing, China, ⁵Bldg 10 Rm 6d47c, National Institutes of Health, Bethesda, MD
Background/Purpose: To investigate a B-cell subpopulation, exhibiting CD19+CD24-CD38hi phenotype, can be a biomarker for diagnosis and disease activity in IgG4 related disease (IgG4-RD). Methods: Circulating…
Abstract Number: 1383 • 2015 ACR/ARHP Annual Meeting
T-Cell Subset Analysis in IgG4-Related Disease and Lymphocyte-Variant Hypereosinophilic Syndrome
Mollie Carruthers¹, Bakul Dalal², Sujin Park³, Graham Slack², Andre Mattman⁴ and Luke Chen⁵, ¹Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²Pathology, University of British Columbia, Vancouver, BC, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴Medical Biochemistry, University of British Columbia, Vancouver, BC, Canada, ⁵Hematology, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: IgG4-related disease (IgG4-RD) and lymphocyte-variant hypereosinophilic syndrome (L-HES) share elevated peripheral eosinophilia and IgE levels as well as common clinical features including atopy, cutaneous…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].